argenx (NASDAQ:ARGX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $617.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 5.40% from the company’s current price. ARGX has been the […]

Sage Therapeutics (NASDAQ:SAGE – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $14.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 192.28% from the company’s previous close. […]

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $15.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 134.74% from the stock’s current price. Several […]

Adicet Bio (NASDAQ:ACET – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. Other equities research analysts also recently issued reports about the stock. Wedbush restated an “outperform” rating and issued a $5.00 target price on shares […]

HC Wainwright restated their buy rating on shares of I-Mab (NASDAQ:IMAB – Free Report) in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a $8.00 price objective on the stock. I-Mab Stock Performance IMAB stock opened at $1.04 on Friday. I-Mab has a 1 year low of $0.99 and a […]

HC Wainwright restated their buy rating on shares of Gevo (NASDAQ:GEVO – Free Report) in a report issued on Wednesday,Benzinga reports. The brokerage currently has a $14.00 price target on the energy company’s stock. HC Wainwright also issued estimates for Gevo’s FY2027 earnings at $0.40 EPS. Separately, UBS Group boosted their price objective on shares […]

HC Wainwright reiterated their buy rating on shares of MiNK Therapeutics (NASDAQ:INKT – Free Report) in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock. HC Wainwright also issued estimates for MiNK Therapeutics’ FY2028 earnings at $0.24 EPS. Separately, Robert W. Baird decreased their price […]

HC Wainwright reissued their neutral rating on shares of Kodiak Sciences (NASDAQ:KOD – Free Report) in a report published on Friday morning,Benzinga reports. The firm currently has a $3.00 price target on the stock. Kodiak Sciences Stock Up 4.3 % KOD traded up $0.23 during trading on Friday, hitting $5.53. The company had a trading […]

HC Wainwright reiterated their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV – Free Report) in a report released on Friday morning,Benzinga reports. The brokerage currently has a $8.00 price target on the stock. HC Wainwright also issued estimates for Plus Therapeutics’ FY2028 earnings at $0.28 EPS. Separately, Ascendiant Capital Markets dropped their price objective […]

Altimmune (NASDAQ:ALT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s price objective would indicate a potential upside of 57.69% from the company’s previous close. A number of […]

Kamada (NASDAQ:KMDA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $11.00 target price on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 89.33% from the stock’s previous close. HC […]

HC Wainwright reissued their neutral rating on shares of DURECT (NASDAQ:DRRX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. Separately, StockNews.com started coverage on DURECT in a research report on Monday. They set a “sell” rating on the stock. View Our Latest Analysis on DURECT DURECT Stock Down 9.8 […]

HC Wainwright restated their buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report report published on Thursday,Benzinga reports. The firm currently has a $36.00 price target on the stock. Several other analysts have also recently issued reports on FDMT. Leerink Partners reaffirmed an “outperform” rating and set a […]

HC Wainwright reaffirmed their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRV – Free Report) in a research note issued to investors on Thursday morning, MarketBeat Ratings reports. The firm currently has a $22.00 price objective on the stock. Other equities research analysts have also issued reports about the stock. BMO Capital Markets restated an […]

Liquidia (NASDAQ:LQDA – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $29.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 186.00% from the stock’s previous close. Several other analysts have […]

HC Wainwright reissued their neutral rating on shares of Co-Diagnostics (NASDAQ:CODX – Free Report) in a report issued on Monday,Benzinga reports. The firm currently has a $1.50 price target on the stock. Co-Diagnostics Price Performance Shares of NASDAQ CODX opened at $1.11 on Monday. Co-Diagnostics has a 1 year low of $1.00 and a 1 […]

HC Wainwright reiterated their buy rating on shares of Soleno Therapeutics (NASDAQ:SLNO – Free Report) in a report published on Monday morning,Benzinga reports. They currently have a $70.00 target price on the stock. Other analysts also recently issued research reports about the company. Oppenheimer boosted their price objective on Soleno Therapeutics from $65.00 to $73.00 […]

HC Wainwright reissued their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a research note published on Monday morning,Benzinga reports. The firm currently has a $10.00 price target on the stock. CMPX has been the subject of several other reports. Wedbush reiterated an “outperform” rating and set a $8.00 price objective […]

HC Wainwright restated their buy rating on shares of Mineralys Therapeutics (NASDAQ:MLYS – Free Report) in a research note published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $30.00 target price on the stock. Mineralys Therapeutics Stock Down 10.3 % Shares of MLYS stock opened at $13.38 on Tuesday. Mineralys Therapeutics has a 1-year […]

Akero Therapeutics (NASDAQ:AKRO – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $50.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 50.02% from the stock’s current price. Akero Therapeutics […]

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Friday,Benzinga reports. They currently have a $30.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 25.37% from the company’s previous close. Several […]

HC Wainwright reaffirmed their neutral rating on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $6.60 price objective on the biopharmaceutical company’s stock. RVNC has been the subject of several other research reports. Needham & Company LLC reissued a “hold” rating […]

HC Wainwright restated their buy rating on shares of OnKure Therapeutics (NASDAQ:OKUR – Free Report) in a research note published on Friday,Benzinga reports. HC Wainwright currently has a $40.00 price target on the stock. A number of other equities analysts have also issued reports on OKUR. Oppenheimer assumed coverage on OnKure Therapeutics in a research […]

HC Wainwright reaffirmed their buy rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research report sent to investors on Friday,Benzinga reports. The firm currently has a $9.00 price objective on the stock. ALLO has been the topic of several other research reports. Truist Financial restated a “buy” rating and issued a […]

HC Wainwright restated their buy rating on shares of Puma Biotechnology (NASDAQ:PBYI – Free Report) in a research report released on Friday,Benzinga reports. They currently have a $7.00 price target on the biopharmaceutical company’s stock. Separately, StockNews.com raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on […]

HC Wainwright reissued their buy rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Tuesday morning,Benzinga reports. They currently have a $70.00 price objective on the stock. Other analysts have also recently issued research reports about the stock. Raymond James raised shares of Disc Medicine from an “outperform” rating […]

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $120.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 106.97% from the stock’s current price. […]

HC Wainwright reaffirmed their buy rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a report issued on Thursday,Benzinga reports. They currently have a $100.00 price target on the stock. A number of other research firms also recently commented on KROS. Scotiabank initiated coverage on Keros Therapeutics in a research note on Wednesday, […]